Some types of cancer cells are surrounded by a dense layer of connective tissue that acts as a barrier to cancer-killing immune cells. That poses a problem for immunotherapies, treatments that depend on interactions […]
The Food and Drug Administration (FDA) has expanded the approved use of the drug ado-trastuzumab emtansine (Kadcyla) to treat some women with HER2-positive breast cancer. Ado-trastuzumab, also called T-DM1, was initially approved by FDA more […]
The potential benefits of vaccines are twofold: In addition to directly protecting those who get the vaccine, they also protect those who don’t. The latter, a phenomenon called herd immunity, occurs as […]
Avelas Biosciences, a California-based clinical-stage oncology company, is developing AVB-620, a novel drug-device combination product for use during cancer surgery. AVB-620 works to improve surgery by detecting cancer in real-time and has […]
Chaos can be surprisingly orderly. While cancer is characterized by uncontrolled cell growth, that growth is, nevertheless, the result of a very particular cascade of events, from carcinogen exposure to genetic mutations. […]
Despite all of the advancements in cancer research and cures, there is one major aspect of the disease that is as under-discussed as it is controversial: patient cost. While the road to […]
MiraDx, a Los Angeles-based company, is committed to discovering meaningful ways to better treat cancer in patients with mutations like and including the KRAS-variant. They are developing answers by applying their novel […]
“HER2 is a gene that codes for a protein sitting on the cell surface and sending signals for the cell to grow and divide,” explains Dr. Daniel Haber, Director at Massachusetts General Hospital […]
